Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Cragg
Energy-guided combinatorial co-optimization of antibody affinity and stability
Abstract Affinity maturation is an essential process in antibody engineering. Although powerful, it is iterative, time-consuming, and can result in trade-offs, where affinity is gained at the cost of important properties, such as specificity and stability. We present a scalable strategy, called LAffAb, that starts from a crystallographic structure of the antibody-antigen complex and introduces combinations of mutations to the antibody to optimize the energy of the complex.
Cell-surface expression of the RNA binding protein U5 snRNP200 on acute myeloid leukemia and other tumor cells is independent of FcγR-mediated interactions
Abstract The development of novel immunotherapeutics for acute myeloid leukemia (AML) is hampered by the limited knowledge of tumor-expressed targets absent on non-malignant cells. We recently identified the RNA binding protein U5 small nuclear ribonucleoprotein 200 kDa (U5 snRNP200) as a novel antigen that is overexpressed on AML blasts in 50% of cases. As a non-canonical membrane protein lacking a transmembrane domain, a cofactor is required for surface expression.
Gas-phase unfolding assay rapidly predicts structure-function relationships in engineered antibodies with tuned flexibilities
Abstract Human (h)IgG2 monoclonal antibodies (mAbs) are potent agonists due, in part, to their ability to undergo disulfide shuffling within their hinge regions. Herein, we describe a rapid, sensitive, collision-induced unfolding (CIU) assay that possesses a predictive relationship between gas-phase protein unfolding and agonism in hIgG2 variants.
Antibody binding geometry and affinity control inhibitory h FcγRIIB receptor signaling
|
Keywords immunotherapy hFcγRIIB agonism antagonism crystal structure epitope affinity receptor triggering antibody Introduction Fc gamma receptors (FcγR) are expressed by multiple cell types and serve to regulate the functions of immunoglobulin G (IgG) antibodies within the body, thereby mediating various aspects of humoral immunity in health and disease.1 A number of genetic polymorphisms and/or copy-number variations in both mouse and human FcγR predispose to, or ameliorate, autoimmune...
By Hayden Fisher, Emma Sutton, Robert Oldham, Richard Bradshaw, Patrick Duriez, Björn L. Frendéus, Gunilla Larsson, Guisi Manfredi, Marisa Martin-Fernandez, Ian Mockridge, Sarah R Needham, Daniel Rolfe, Christian M. Orr, Kallum Patel, Alex Simpson, Jinny Kim, Sarel J. Fleishman, Jonathan W. Essex, Ivo Tews, Mark Cragg, Ali Roghanian, Ingrid Teige, Ulla-Carin Tornberg, Christopher J. Tynan, Abigail Pendower, Ariel Tennenhouse
|
Cell Press
Verified
Realizing the potential of agonistic antibody immunotherapy
Abstract Agonistic antibodies mimic the activities of native ligands by initiating signalling by the receptors they target. As stimulators of immune-cell surface receptors, they offer the prospect of resetting immune responses in autoimmune conditions or initiating new or stronger reactions in contexts such as cancer immunotherapy. Despite these theoretical advantages and preclinical promise, the use of agonistic antibodies has so far delivered only limited benefit to patients.
Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy - Nature Communications
Abstract Despite significant clinical progress, checkpoint blockade remains limited by variable response rates, resistance, and toxicity. Activating costimulatory receptors offers a promising alternative to enhance anti-tumor immunity. However, there is insufficient understanding of how to mimic physiological membrane-anchored costimulatory ligands.
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs
Fc receptors (FcR) play a key role in coordinating responses from both the innate and adaptive immune system. The inhibitory Fc gamma receptor (FcγRIIB/CD32B; referred to as FcγRII in mice) restrains the immune response, specifically through regulating immunoglobulin G (IgG) effector functions. FcγRII-deficient mice demonstrate elevated incidence and severity of autoimmunity and increased responses to immunization and infections.
Special Issue “Advances in Genome Regulation in Cancer”
Cancer is globally increasing. Since 2010 it has risen in incidence by 26.3%, with mortality growing by 20.9% and cancer-associated invalidity increasing by 16.0% [1], painfully demonstrating our ongoing inability to win the “war on cancer” as proclaimed by US President Nixon in 1971. It is also sobering to acknowledge in the post-genomic era that cancer is far more complex and poorly understood than previously appreciated based solely on somatic mutation theory [2].
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression - Leukemia
Abstract The first-in-class inhibitor of exportin-1 (XPO1) selinexor is currently under clinical investigation in combination with the BTK inhibitor ibrutinib for patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin lymphoma. Selinexor induces apoptosis of tumour cells through nuclear retention of tumour suppressor proteins and has also recently been described to modulate natural killer (NK) cell and T cell cytotoxicity against lymphoma cells.
Genetic dissection of a major haplotype associated with arthritis reveal FcγR2b and FcγR3 to act additively
Abstract A haplotype with tightly linked Fc gamma receptor (FcγR) genes is known as a major locus controlling immune responses and autoimmune diseases, including arthritis. Here, we split a congenic fragment derived from the NOD mouse (Cia9) to study its effect on immune response and arthritis in mice. We found that arthritis susceptibility was indeed controlled by the FcγR gene cluster and a recombination between the FcγR2b and FcγR3 loci gave us the opportunity to separately study their impact.
Engineered antibodies to combat viral threats
NEWS AND VIEWS 18 November 2020 As the COVID-19 pandemic rages globally, interest in antiviral treatments has never been higher. Antibodies are key defence components, and engineering them to better exploit their natural functions might boost therapeutic options. Xiaojie Yu & Xiaojie Yu is in the Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, SouthamptonSO16 6YD, UK. Contact Mark S. Cragg Mark S.
How Weaponizing The Body's Immune System Can Deliver A Cure For Cancer
Fighting back. Shutterstock We’re beginning to treat cancer in a whole new way. Rather than killing cancer cells directly with chemo or radiotherapy, the latest treatments are designed to promote the body’s natural immune control over the disease. So-called immunotherapy works to stimulate the body’s own immune system to destroy the cancer.
How weaponising the body's immune system can deliver a cure for cancer
We’re beginning to treat cancer in a whole new way. Rather than killing cancer cells directly with chemo or radiotherapy, the latest treatments are designed to promote the body’s natural immune control over the disease. So-called immunotherapy works to stimulate the body’s own immune system to destroy the cancer. It is not a new concept and was first described more than a century ago, but for the first time it is beginning to deliver long-lasting responses, which some are daring to call cures.
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms Kirstie L. S. Cleary, H. T. Claude Chan, Sonja James, Martin J. Glennie, Mark S. Cragg The Journal of Immunology May 15, 2017, 198 (10) 3999-4011; DOI: 10.4049/jimmunol.1601473
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms Kirstie L. S. Cleary, H. T. Claude Chan, Sonja James, Martin J. Glennie, Mark S. Cragg The Journal of Immunology April 12, 2017, 1601473; DOI: 10.4049/jimmunol.1601473
T-cell immunotherapy: How weaponising the body's immune system can deliver a cure for cancer
We're beginning to treat cancer in a whole new way. Rather than killing cancer cells directly with chemo or radiotherapy, the latest treatments are designed to promote the body's natural immune control over the disease. So-called immunotherapy works to stimulate the body's own immune system to destroy the cancer. It is not a new concept and was first described more than a century ago, but for the first time it is beginning to deliver long-lasting responses, which some are daring to call cures.
How weaponising the body's immune system can deliver a cure for cancer
We’re beginning to treat cancer in a whole new way. Rather than killing cancer cells directly with chemo or radiotherapy, the latest treatments are designed to promote the body’s natural immune control over the disease. So-called immunotherapy works to stimulate the body’s own immune system to destroy the cancer. It is not a new concept and was first described more than a century ago, but for the first time it is beginning to deliver long-lasting responses, which some are daring to call cures.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack